Ovid Therapeutics (FRA:1OT) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1OT Ovid Therapeutics Inc FRA:1OT
34 GF Score
Price €2.36
GF Value €0.83
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ovid Therapeutics Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

FRA:1OT
34GF Score
Ovid Therapeutics Inc FRA:1OT
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ovid Therapeutics (FRA:1OT) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued. The current stock price of €2.36 is trading 184.3% above its estimated GF Value™ of €0.83. GuruFocus considers Ovid Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:1OT:

  • Interest Expense (Positive):
  • GF Value™: €0.83 vs. price of €2.36 (184.3% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the FRA:1OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ovid Therapeutics Business Description

Other Exchanges OVID:USA
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
34GF Score

Get the complete analysis for FRA:1OT

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.36
Price
€0.83
GF Value